Where does Medichem, S.A. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Medichem, S.A. ranks #36,430 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Medichem, S.A. hold?

Medichem, S.A. holds 7 US utility patents granted between 2015 and 2025, spanning 9 technology areas.

What is Medichem, S.A.'s Innovation Score?

Medichem, S.A. has an Innovation Score of 30.6 out of 100 (35th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Medichem, S.A. focus on?

Medichem, S.A.'s top technology area is C07D (Heterocyclic Compounds) with 3 patents, ranking #1,866 of 3,165 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Medichem, S.A.'s patent grant rate increasing or decreasing?

Medichem, S.A.'s recent grant velocity is +0% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Medichem, S.A.'s patents?

Medichem, S.A.'s patents average 15.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Medichem, S.A. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Medichem, S.A.

USPTO PatentsView assignee record - 7 granted patents across 9 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Medichem ranks #36,430 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 9 technology areas.

#36,430
of 49,997 US assignees by volume: 35th percentile
by Innovation Score (30.6/100): 15.7
avg claims per patent: +0%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R36430 · Foreign Corporation #36,430 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL

GRANTS-MICRO 7 grants
MID-PACK #36,430/49,997
PHOTO-FINISH Medal
CPC-NARROW C07D · 9 areas
INNOV-THIN 30.6/100
CLAIMS-RICH 15.7 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-FLAT +0% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Medal Technologies, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Medichem’s 30.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.2 pts (24%) Velocity 3.3 pts (11%) Breadth 10.6 pts (35%) Claim depth 9.4 pts (31%)

Qualcomm Incorporated · highest

85
Medichem · this assignee

31
3D Lighting… · lowest

7

What this shows Medichem's Innovation Score is 30.6/100 (35th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Medichem?

Each dot is one of Medichem’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Medichem’s own 15.7 claims/patent is ABOVE the 15.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Medichem vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Medichem's grants concentrate

Medichem, S.A. is a focused PatentsView assignee: 9 CPC subclasses with 42.9% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2015 (3 grants) versus a trough of 1 in 2022. By volume, Medichem sits between Medal Technologies, LLC and Medincell S.A..

Medichem's three-year grant acceleration

Medichem, S.A. shows 1 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Medal

7
Medeor Therapeuti…

7
Medical Innovatio…

7
Medical Intellige…

7
Medicom Innovatio…

7
Medigen

7
Medigenebio

7
Medincell

7
Medichem ◀

7

What this shows Medichem holds 7 patents at rank #36,364, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Medichem

By rank, the assignees closest to #36,364 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Medichem's primary technology class.

Medichem's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

31 35th percentile higher than 35% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Medichem, S.A. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	42.9%
2021	2	28.6%
2022	1	14.3%
2025partial year	1	14.3%

Which technologies does Medichem, S.A. patent most?

C07D - Heterocyclic Compounds 3

C07C - Acyclic OR Carbocyclic Compounds 2

B01J - Chemical OR Physical Processes, e.g. Catalysis OR Colloid CHEMISTRY; Their Relevant Apparatus 2

C08L - Compositions OF Macromolecular Compounds 1

C08B - POLYSACCHARIDES; Derivatives Thereof 1

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 1

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Medichem, S.A.'s patent record in context - here's where to go next.

Medichem, S.A.'s lead technology class is C07D (Heterocyclic Compounds), 42.9% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #36,430 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Medichem, S.A. against Medal Technologies, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 30.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.